Paul Conyngham launches Gamgee for personalized dog cancer vaccines

In short: Paul Conyngham has launched a startup called Gamgee that says it will make personalized mRNA cancer vaccines for dogs.

What happened

Paul Conyngham, an Australian tech entrepreneur, announced a new company called Gamgee. The company says it will offer “personalised mRNA cancer vaccines for dogs.” An mRNA vaccine is a treatment that gives the body instructions, like a recipe card, to help the immune system spot and fight a specific target.

Gamgee’s story centers on Rosie, Conyngham’s dog, who had cancer. Conyngham has said he used tools like ChatGPT and “computational genomics” (software that helps analyze DNA, the body’s instruction code) to design a personalized vaccine for Rosie’s tumor. He has said several of her tumors shrank.

The Verge previously reported that it is hard to tell what role AI played and whether the mRNA vaccine caused the improvement, because Rosie received the vaccine alongside another therapy. Researchers also told The Verge that the public claims risk giving AI too much credit and downplaying the work done by people.

Gamgee is backed by Y Combinator, a well-known startup incubator. The company says it is recruiting for its first clinical trials in Australia, with a waitlist elsewhere. On its website, Gamgee claims about 75 percent tumor reduction in its “first documented case,” while noting this is based on a single case and timing can vary. Prices are not listed.

Why it matters

Many pet owners are looking for new cancer options, but early claims can be confusing. This launch is a reminder to look for clear evidence from controlled trials, not just one success story, before assuming a treatment works.

Source: The Verge AI